Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia / Marconi, G; Piciocchi, A; Audisio, E; Priolo, G; Papayannidis, C; Martelli, M; Paoloni, F; Lemoli, RM; Bocchia, M; Lanza, F; Lico, A; Ciceri, F; Della Porta, MG; Frigeni, M; Giaccone, L; Beltrami, G; Borlenghi, E; Di Chio, MC; Selleri, C; Crea, E; Urbino, I; Sartor, C; Minotti, C; Guolo, F; La Sala, E; Nanni, J; Simonetti, G; Bochicchio, MT; Saglio, G; Venditti, A; Vignetti, M; Fazi, P; Martinelli, G. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 140:Supplement 1(2022), pp. 1705-1707. [10.1182/blood-2022-157393]
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
Marconi, G;Priolo, G;Papayannidis, C;Lemoli, RM;Lanza, FMembro del Collaboration Group
;Sartor, C;Minotti, C;Bochicchio, MT;
2022
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
